Home » Stocks » OCUL

Ocular Therapeutix, Inc. (OCUL)

Stock Price: $20.33 USD -1.11 (-5.18%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.53B
Revenue (ttm) 12.31M
Net Income (ttm) -96.04M
Shares Out 62.99M
EPS (ttm) -1.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $20.33
Previous Close $21.44
Change ($) -1.11
Change (%) -5.18%
Day's Open 21.19
Day's Range 20.26 - 21.45
Day's Volume 690,137
52-Week Range 4.06 - 22.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Zacks Investment Research - 1 week ago

Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.

Business Wire - 2 weeks ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Zacks Investment Research - 3 weeks ago

The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021.

Business Wire - 3 weeks ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovativ...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovativ...

Zacks Investment Research - 2 months ago

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 26.09% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...

Seeking Alpha - 2 months ago

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 8.70% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Seeking Alpha - 2 months ago

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkp...

Other stocks mentioned: CASI, INCY, ZLAB
Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Zacks Investment Research - 2 months ago

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Zacks Investment Research - 2 months ago

As of late, it has definitely been a great time to be an investor in Ocular Therapeutix (OCUL).

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Seeking Alpha - 3 months ago

Ocular Therapeutix: Buy What 80% Of Patients Want

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovat...

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innova...

Business Wire - 4 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc.

Business Wire - 4 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

Business Wire - 4 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

Business Wire - 4 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

Seeking Alpha - 4 months ago

Ocular - Small-Cap Pharmaceutical Growth Story

Seeking Alpha - 5 months ago

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Ocular Therapeutix (NASDAQ:OCUL) moved higher by 1% in pre-market trading after the company reported Q2 results.

Business Wire - 5 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc.

Zacks Investment Research - 5 months ago

Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 5 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc.

Zacks Investment Research - 5 months ago

Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovativ...

Business Wire - 6 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc.

Business Wire - 6 months ago

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovati...

Seeking Alpha - 6 months ago

Cloud Charts Tell Me To Wait Until I See Sunshine

Other stocks mentioned: INCY, ISRG, LMT, MHO
Seeking Alpha - 6 months ago

Ocular Therapeutix Is A Good Value Based On Its Strong Technology Platform

Zacks Investment Research - 7 months ago

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other stocks mentioned: ATXI, CNCE, MEIP, NERV
Zacks Investment Research - 7 months ago

Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening

Other stocks mentioned: AUY, CRON, FRO, GLUU
The Motley Fool - 7 months ago

An offering of its shares has bolstered its balance sheet.

Seeking Alpha - 7 months ago

Ocular Therapeutix: This Platform Technology Story Continues To Impress

Seeking Alpha - 8 months ago

Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Ocular Therapeutix (NASDAQ:OCUL) were unchanged in pre-market trading after the company reported Q1 results.

About OCUL

Ocular Therapeutix, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conj... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2014
CEO
Antony Mattessich
Employees
161
Stock Exchange
NASDAQ
Ticker Symbol
OCUL
Full Company Profile

Financial Performance

In 2019, OCUL's revenue was $4.23 million, an increase of 112.41% compared to the previous year's $1.99 million. Losses were -$86.37 million, 44.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 25.50, which is an increase of 25.43% from the latest price.

Price Target
$25.50
(25.43% upside)
Analyst Consensus: Buy